Shares of Cullinan Therapeutics Inc. (CGEM) surged 5.01% on Thursday after the biopharmaceutical company reported better-than-expected earnings for the third quarter of 2024.
The company reported a quarterly adjusted loss of $0.69 per share, beating analysts' consensus estimate of a $0.81 loss per share. While Cullinan had no reported revenue for the quarter, its net loss of $40.56 million was narrower than anticipated. The earnings beat was driven by cost controls and operational efficiencies.
Analysts have been cautiously optimistic on Cullinan, with all 10 analysts covering the stock rating it a "buy" or "strong buy." The average 12-month price target for the stock is $30, reflecting potential upside from current levels. With the better-than-expected Q3 results, the Street may revise its estimates higher going forward.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。